By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Life
Technologies Corp. et al. v. Kappos et al.
1:12-cv-01518;
filed December 28, 2012 in the Eastern District of Virginia

• Plaintiffs: 
Life Technologies Corp.; Geneart AG; Applied Biosystems, LLC
• Defendants: 
David J. Kappos; Office of the Attorney General

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent Nos. 8,211,699 ("Methods for
Culturing Pluripotent Stem Cells in Suspension Using ERBB3 Ligands,"
issued July 3, 2012), 8,224,578 ("Method and Device for Optimizing a
Nucleotide Sequence for the Purpose of Expression of a Protein, issued July 17,
2012), 8,221,607 ("High Speed, High Resolution Compositions, Methods and
Kits for Capillary Electrophoresis," issued July 17, 2012), 8,232,582 ("Ultra-Fast
Nucleic Acid Sequencing Device and a Method for Making and Using the Same,"
issued July 31, 2012), 8,247,219 ("Device and Method for Multiple Analyte
Detection," issued August 21, 2012), 8,262,900 ("Methods and Apparatus
for Measuring Analytes Using Large Scale FET Arrays," issued September 11,
2012), 8,268,149 ("Electro-Blotting
Devices, Systems, and Kits, and Methods for Their Use," issued September
18, 2012), 8,268,249 ("Analytical Device with Lightguide Illumination of Capillary
and Microgroove Arrays," issued September 18, 2012), 8,246,806 ("Multi-Capillary
Array Electrophoresis Device," issued August 21, 2012), and 8,287,881 ("Synthetic
Gagpol Genes and Their Uses," issued October 16, 2012).  View the complaint here.

Abbvie
Biotechnology, Ltd. v. Kappos
1:12-cv-01511;
filed December 28, 2012 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,216,583 ("Formulation of Human
Antibodies for Treating TNF-α Associated Disorders,"
issued July 10, 2012). View the complaint here.

Human Genome
Sciences, Inc. v. Kappos
1:12-cv-01509;
filed December 28, 2012 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,211,439 ("Albumin Fusion
Proteins Comprising Insulin Polypeptides," issued July 3, 2012). View the
complaint here.

Shionogi
& Co., Ltd. v. Sandoz Inc.
3:12-cv-07907;
filed December 28, 2012 in the District Court of New Jersey

Infringement
of U.S. Patent No. 8,247,402 ("Crystal Form of Pyrrolidylthiocarbapenem
Derivative," issued August 21, 2012) following a Paragraph IV
certification as part of Sandoz's filing of an ANDA to manufacture a generic
version of Shionogi's (and Janssen's) Doribax® (doripenem injection, used to
treat complicated intra-abdominal infections and complicated urinary tract
infections, including pyelonephritis). 
View the complaint here.